Loading…
← CockpitCompetitor Analysis › 268A.T Rigaku Holdings CorporationOpen in the cockpit ↗

Rigaku Holdings Corporation268A.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Japanese maker of X-ray analysis and diffraction instruments used in materials research and semiconductor labs.

≈ A niche scientific-instruments maker like a smaller BrukerMomentum laggard 3
Mkt cap
$1.85B
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$22.2M
20-day average traded
Fwd P/E
23.1×
forward earnings
ROIC−WACC
-0.6 pp
WACC 9.1%
Hurdle
+4 pp
Req g minus delivered
Next earnings
86 days
12 Feb 2027
Close · JPY¥1,318
1D+4.0%
1W-4.8%
1M-11.0%
3M-36.9%
6M-53.9%
YTD+7.4%
1Y+32.9%
ATR %7.7%
52w lowhigh61.2% off high

What Rigaku does

Japanese maker of X-ray analysis and diffraction instruments used in materials research and semiconductor labs.

Sells costly analytical instruments to labs and factories, and earns repeat income from consumables, service and software on the installed base. Chipmakers' metrology needs and research budgets drive orders. It listed in 2024 after a period of private-equity ownership.

In one line: A niche scientific-instruments maker like a smaller Bruker.

Products and services

  • X-ray diffraction instruments
  • X-ray fluorescence analyzers
  • Thermal analysis instruments

Customers

  • Materials/semiconductor research labs
  • Universities
  • Pharmaceutical companies

Where it sits in the supply chain

  • Industrials
  • Scientific instruments
  • X-ray diffraction/fluorescence…

What could go right

  • Semiconductor/battery materials R&D spend

What could go wrong

  • Research budget cyclicality

Moat: narrow (process know-how, brand). Specialized X-ray analysis expertise and instrument brand recognition among materials scientists.

Headquarters: Tokyo, Japan · Founded: 1951 · Employees: 1,971

Named competitors

  • Bruker BRKR
  • JEOL 6951.T
  • Malvern Panalytical private or unlisted

Rigaku at a glance

Size Rigaku (268A.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.85B, the 512th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,318 on 18 Nov 2026.

Performance Over six months the shares fell 53.9%, against +3.5% for the median peer and -1.4% for the Japan market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 8.9% over the last twelve months (peer median +14.5%); the operating margin is 16.3% (peer median 13.6%).

Valuation It trades at 23.1× forward earnings against a peer median of 29.4× (8th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.6 points below its cost of capital (9.1% WACC).

Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 102268A.T 47
Six months, rebased to 100: Rigaku against the median of its 20 peers (local-currency closes).

Rigaku financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥95.4B¥94.2B¥90.7B¥79.9B¥62.7B
Revenue growth—+4%+13%+27%—
Gross profit¥54.5B¥48.9B¥51.3B¥43.1B¥34.4B
EBITDA¥21.2B¥22.4B¥23.4B¥19.8B¥15.2B
Net income¥9.61B¥11.4B¥13.6B¥10.9B¥911M
Free cash flow¥5.58B¥3.56B¥8.74B¥8.94B¥4.67B
Capital expenditure¥5.38B¥6.65B¥6.36B¥2.83B¥2.72B
Total debt¥66.7B¥62.2B¥61.6B¥62.1B¥63.3B

Quarterly statements and history in the cockpit →

Rigaku competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%SKAN6960MED1066POLYMED7716CHEMMLMAT301363EMBLAKMTSINSP8086BONEXVCYTBFLYESTA268A.T6-month return →1-month return →
Up and to the right = strong over both horizons. Rigaku is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%20×40×60×SKAN6960MED1066POLYMED7716CHEMMLMAT301363EMBLAXRAYINSPBONEXVCYT6699268A.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Rigaku is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%SKAN696010667716CHEMMLMAT301363EMBLAXRAYINSPBONEXVCYT6699268A.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Rigaku is the large dot.

Rigaku competitors and peer comparison

Head to head with its named competitors (268A.T vs BRKR vs 6951.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Rigaku 268A.T$1.85B-54%+9%16%23.1×18.3%
Bruker BRKR$9.66B+43%+2%10%27.0×25.4%
JEOL 6951.T$2.12B-2%-15%12%15.5×22.2%

How Rigaku compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Rigaku against its 20 peers (data as of 18 Nov 2026)
Measure268A.TPeer medianRank in peer set
1-month return-11.0%-2.0%4th lowest of 21
6-month return-53.9%+3.5%lowest of 20
Distance from 52-week high-61.2%-21.0%lowest of 21
Revenue growth (TTM)+8.9%+14.5%8th lowest of 21
Operating margin16.3%13.6%8th highest of 21
Forward P/E23.1×29.4×8th cheapest of 17
Growth the price implies (Req g, 7 yrs)18.3%12.6%3rd most demanding of 14
Growth delivered (Del g)+14.5%+12.9%6th highest of 14
Hurdle (Req g minus delivered)+3.8 pp-10.3 pp3rd most demanding of 14
ROIC minus cost of capital-0.6 pp+0.6 pp11th highest of 21
EV / EBITDA15.7×17.9×8th cheapest of 16
Net debt / EBITDA1.9×-1.0×5th most indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a

Questions

Who are Rigaku's main competitors?
Named competitors: Bruker (BRKR), JEOL (6951.T), Malvern Panalytical (private or unlisted). The cockpit's measured peer set (industry) also includes Molbio Diagnostics (MOLBIO.NS), SKAN (SKAN.SW), Fukuda Denshi (6960.T), Medartis (MED.SW), Shandong Weigao Group Medical Polymer (1066.HK), Poly Medicure (POLYMED.NS).
Is Rigaku expensive compared with its peers?
On forward p/e it trades at 23.1× against a peer median of 29.4×, 8th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Rigaku stock performed?
Over six months to 18 Nov 2026 the shares returned -53.9% against +3.5% for the median peer; over one year +32.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.